Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $792.65 Consensus Price Target from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $792.6522.

REGN has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research note on Monday, May 18th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Finally, Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Ellerson Group Inc. ADV increased its holdings in Regeneron Pharmaceuticals by 49.2% in the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after buying an additional 2,671 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Regeneron Pharmaceuticals by 118.1% during the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after purchasing an additional 74,350 shares during the last quarter. TD Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 15.9% during the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after purchasing an additional 51,407 shares during the last quarter. Stevens Capital Management LP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $792,000. Finally, Mackenzie Financial Corp increased its stake in shares of Regeneron Pharmaceuticals by 26.8% during the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock worth $72,321,000 after purchasing an additional 27,205 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $632.90 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a market capitalization of $66.91 billion, a P/E ratio of 15.42, a P/E/G ratio of 1.39 and a beta of 0.25. The company’s fifty day moving average is $663.51 and its two-hundred day moving average is $728.62. Regeneron Pharmaceuticals has a 1 year low of $517.39 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.22 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.